Comprehensive metabolomic profiling of plasma from patients (pts) with metastatic urothelial carcinoma (mUC) receiving immune checkpoint inhibitors (ICI) or platinum-based chemotherapy (PBC).
Talal El Zarif(Yale University), Guru Sonpavde(AdventHealth Orlando), Praful Ravi(Dana-Farber Cancer Institute), Dory Freeman(Dana-Farber Cancer Institute), Clary B. Clish(Broad Institute), Arvind Ravi(Broad Institute), Bradley A. McGregor(Harvard University), Elio Adib(Dana-Farber Brigham Cancer Center), Martha Tuff(Dana-Farber Cancer Institute), Jonathan Thomas(Beth Israel Deaconess Medical Center), Sachet A. Shukla(The University of Texas MD Anderson Cancer Center), Charlene Mantia(Dana-Farber Cancer Institute)
Cited by 1
Related Papers
Regulation of Ferroptotic Cancer Cell Death by GPX4
|Cell|2014|7.5k
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
|Cell|2015|4.2k